Abexinostat (CRA-024781) is a novel, broad-spectrum HDAC inhibitor based on hydroxamic acid that has demonstrated antitumor activity in preclinical studies and is currently in phase I clinical trials for cancer [57]. Here, HDAC9 is linked to cancer.